Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT05619562

Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

Conditions: Non Small Cell Lung Cancer, Circulating Tumor Cell

Sex: All

Ages: 18 Years – N/A

Enrollment: 166

Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic

Location: Czechia

Summary

To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

Eligibility Criteria

Inclusion Criteria:Non-small cell lung cancer, non-metastaticExclusion Criteria:Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05619562). StuddyBuddy aggregates publicly available trial information.